Indications
Vpriv is indicated for long-term enzyme-replacement therapy (ERT) in patients with type-1 Gaucher disease.
Composition
- Active substance
- velaglucerase alfa
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Vpriv
- Active substance
- velaglucerase alfa
- ATC code
- A16AB10
- Therapeutic area
- Gaucher Disease
- Marketing authorisation holder
- Takeda Pharmaceuticals International AG Ireland Branch
- Status
- Authorised
- EU authorisation
- 26 Aug 2010